1. Home
  2. CYTK vs TRMB Comparison

CYTK vs TRMB Comparison

Compare CYTK & TRMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$60.83

Market Cap

10.7B

Sector

Health Care

ML Signal

HOLD

Logo Trimble Inc.

TRMB

Trimble Inc.

SELL

Current Price

$60.89

Market Cap

11.8B

Sector

Industrials

ML Signal

SELL

Company Overview

Basic Information
Metric
CYTK
TRMB
Founded
1997
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
11.8B
IPO Year
2004
1996

Fundamental Metrics

Financial Performance
Metric
CYTK
TRMB
Price
$60.83
$60.89
Analyst Decision
Buy
Strong Buy
Analyst Count
22
12
Target Price
★ $109.90
$79.50
AVG Volume (30 Days)
1.8M
★ 2.0M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
$13,368,000.00
★ $3,798,700,000.00
Revenue This Year
$70.12
$9.58
Revenue Next Year
$183.63
$7.87
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 3.33
52 Week Low
$54.30
$47.92
52 Week High
$88.31
$84.42

Technical Indicators

Market Signals
Indicator
CYTK
TRMB
Relative Strength Index (RSI) 24.31 63.29
Support Level $59.05 $55.78
Resistance Level $67.04 $62.00
Average True Range (ATR) 2.06 1.49
MACD -0.37 0.16
Stochastic Oscillator 3.95 90.68

Price Performance

Historical Comparison
CYTK
TRMB

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About TRMB Trimble Inc.

Trimble Inc is a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has three reportable segments: Architects, Engineers, Construction, and Owners (AECO). This segment provides software solutions that sell through a direct channel to customers in the construction industry. Field Systems. This segment provides hardware and associated software solutions that sell through dealer partner channels. Transportation and Logistics (T&L). This segment provides solutions for customers working in long-haul trucking and freight shipping markets.

Share on Social Networks: